NED Medical is developing CombiSphere, a proprietary Y90 radioembolization therapy that enhances tumor coverage and improves dosimetry for liver cancer treatment. This technology aims to transition radioembolization from a palliative approach to a curative one, addressing the high mortality rates and limited treatment outcomes associated with liver cancer.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Liver cancer is a leading cause of cancer deaths globally, characterized by poor survival rates and limited efficacy of current treatments. Radioembolization, a common treatment, often serves as a palliative measure with suboptimal patient outcomes. There is a need for improved radioembolization therapies that enhance tumor coverage and dosimetry to transition the treatment from palliative to curative.
Solution
NED Medical is developing CombiSphere, a Y90 radioembolization therapy designed to improve the treatment of liver cancer. CombiSphere utilizes proprietary materials to optimize particle size and density, emission activity, and radiopacity, resulting in enhanced tumor coverage and improved dosimetry. This innovative approach aims to transform radioembolization into a curative treatment option, addressing the limitations of existing palliative methods and improving survival rates for patients with liver cancer. By optimizing key characteristics of the Y90 microspheres, CombiSphere seeks to deliver more effective and targeted radiation therapy to liver tumors.
Target Audience
The primary target audience includes interventional radiologists, oncologists, and hospitals specializing in liver cancer treatment.
Features
- Proprietary materials for optimized microsphere size and density
- Enhanced emission activity per particle for increased therapeutic effect
- Radiopaque microspheres for improved visualization and dosimetry planning
- Optimized tumor coverage for more complete treatment of cancerous tissue
- Improved dosimetry for precise and targeted radiation delivery